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Table 1—Conﬂict of interest disclosures for the 2010 Professional Practice Committee
Member Employment Research grant
Other research
support
John Anderson, MD The Frist Clinic, Nashville, TN None None
John Buse, MD, PhD University of North Carolina Amylin*, Eli Lilly*, Hoffman LaRoche*,








Martha Funnell University of Michigan None None
Robert Gabbay, MD Pennsylvania State College of
Medicine, Hershey, PA
None None




Jane Kadohiro, DrPH, APRN,
CDE
The Queens Medical Center,
Honolulu, HI
None None








Michelle Magee, MD Medstar Diabetes Institute,
Washington, DC
sanoﬁ-aventis*, Microsoft*, Novo
Nordisk*, Esai*, Dexcom*, Takeda*
None





Patrick O’Connor, MD, MPH HealthPartners Research Foundation,
Bloomington, MD
NHLBI*, NIDDK*, NIA*, AHRQ* None
Peter Reaven, MD Phoenix VA Medical Center Amylin/Lilly* None
Susan Braithwaite, MD Endocrine Consultants & Care S.C.,
Evanston, IL
None None
Guillermo Umpierrez, MD Emory University, Atlanta, GA sanoﬁ-aventis*, Baxter*, Takeda* None
Stuart Weinzimer, MD Yale University, New Haven, CT Medtronic Diabetes* None
Carol Wysham, MD Rockwood Clinic, Spokane, WA None None





Judy Fradkin, MD (Ex ofﬁcio) National Institute of Diabetes,
Digestive and Kidney Diseases,
Bethesda, MD
None None





Sue Kirkman, MD (Staff) American Diabetes Association,
Alexandria, VA
None None
Continued on next page
Information is up to date as of 1 November 2010. *Amount $10,000/year.
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Member Speakers’ bureau/honoraria Ownership interest Consultant/advisory board Other





J.B. None Insulet* (Sold 2010) Amylin*, BD Research Laboratories,
Bayhill Therapeutics, Eli Lilly,
Hoffman LaRoche*, LipoScience,
Merck, Novo Nordisk, Liposcience,
GI Dynamics, Versartis, BioDel,
Orexigen, Exsulin, University of
Oxford*, Spherix (all through
contracts with UNC)
None




R.G. Novo Nordisk, Merck None Animus, Roche, BD Research
Laboratories, Home Access Health
Corporation, Boehringer Ingleheim
None
S.I. Novo Nordisk None Takeda, Merck, Amylin, Medtonic Eli Lilly* (Expert Witness)
J.K. None None None None
D.L. Novo Nordisk* None Novo Nordisk*, Merck, Leerink
Swann*, Mannkind, Abbot





S.M. None None Daiichi-Sankyo None
P.O. None None None None
P.R. Merck None Bristol Myers Squibb, AstraZeneca None
S.B. None None None None
G.U. None None None None
S.W. Animas/ Lifescan, Eli Lilly*,
Novo Nordisk
Insuline Animas/Lifescan, Biodel, Bayer, Roche,
Insuline
None
C.W. Amylin Pharmaceuticals*, Eli
Lilly*, Merck*, Novo
Nordisk, sanoﬁ-aventis
None Amylin Pharmaceuticals*, Boeringher
Ingleheim
None
G.Y. Novo Nordisk None None None
J.F. None None None None
S.D. None None None None
S.K. None None None None
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